Citamint Tablet 50/500 mg (Sitagliptin Phosphate, Metformin Hydrochloride)
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Ilyun Pharmaceutical Co., Ltd.
MFDS item code 201603080 · Approved 2016.05.30
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help patients with type 2 diabetes who need to take sitagliptin and metformin together in managing their blood sugar levels. By administering it in conjunction with diet and exercise therapy, it can more effectively manage blood sugar. This helps maintain stable blood glucose levels for better diabetes management, thus demonstrating positive effects on blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication can cause serious allergic reactions, although rare, so if symptoms like skin rash or difficulty breathing occur, discontinue use immediately and seek medical attention. This drug can cause serious side effects, including pancreatitis, which is inflammation of the pancreas. If abdominal pain, vomiting, or severe abdominal discomfort appears after use, visit a hospital immediately. Patients with severely impaired kidney function, severe infections, or dehydration should not take this medication. Patients with heart-related diseases such as heart failure or acute myocardial infarction are also prohibited from taking this medication, and it should be discontinued before and after tests using iodinated contrast agents. Women who are pregnant or may become pregnant, as well as those who are breastfeeding, should not take this medication. This medication may pose a higher risk of hypoglycemia and lactic acidosis in patients with irregular meals, nutritional deficiencies, or engaging in intense exercise. Regular kidney function and blood tests should be conducted during treatment, especially in older adults or those with compromised kidney function, who require more careful management. Excessive alcohol consumption can induce a dangerous condition called lactic acidosis from this medication, so it should be avoided. If surgery is to be performed, this medication should be stopped 48 hours prior to surgery and resumed only after confirming that kidney function has returned to normal post-surgery. When used with other hypoglycemic agents, hypoglycemic symptoms may occur, necessitating careful monitoring of blood sugar levels and potential dose adjustments as needed. Gastrointestinal disorders such as diarrhea, nausea, vomiting, abdominal pain, and headaches may occur during treatment, so consult a doctor if symptoms are severe. This medication can cause vitamin B12 deficiency in some patients, so it's advisable to regularly check vitamin B12 levels. If blisters or rashes develop on the skin during treatment, inform a doctor immediately, and consider discontinuing the medication if severe joint or muscle pain arises. In cases of overdose, general treatment can be undertaken, and blood dialysis can be performed to remove the drug if necessary, so care should be taken not to exceed the prescribed dose.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container that is not exposed to air, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effect of the medication for a longer period.
Bright pink oval film-coated tablet
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Ilyun Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.